Esmolol Hydrochloride Injection
Product Images NDC 51662-1427

This is a table that shows the frequency of clinical trial adverse reactions for a medication called BREVIBLOC (Esmolol Hydrochloride). The table displays the system organ class, preferred MedDRA term, and their frequency. The adverse reactions with a frequency greater than 3% are hypotension (both asymptomatic and symptomatic) with a frequency of 25% and 12%, respectively, infusion site reactions with a frequency of 8%, nausea with a frequency of 7%, and dizziness and somnolence both with a frequency of 3%. The text also states that hypotension was resolved during the medication's infusion in 63% of patients, and in 80% of the other patients after discontinuation of the infusion.*

This is a description of Table 4, containing three different formulations of BREVIBLOC injection with varying strengths of Esmolol Hydrochloride and other ingredients, including Sodium Chloride and Sodium Acetate. The formulations are prepared using USP-grade ingredients and adjusted to a pH range of 4.5-5.5. The table also lists the quantity of water and other ingredients added to each formulation, ranging from 10 mL to 250 mL.*

This is a table showing step-wise dosing for a medication. It includes optional loading doses and increases in dosage over different time periods, with the maximum dosage being 200 mcg per kg per minute.*

This appears to be a label or name of a medical device, possibly a medication delivery system, with a "medication port" designed for withdrawing an initial bolus and a "delivery port". The rest of the text is not legible.*

This is a description of Brevibloc Premixed Injection, which is used for intravenous use only. It contains 10mg/mL of Esmolol Hydrochloride in Sodium Chloride and is available in a 250 mL Iso-Osmotic container. The solution has no preservatives and a single-use is recommended. Each mL contains 10mg Esmolol Hydrochloride USP, 59 mg Sodium Chloride USP, 2.8 mg Sodium Acetate Trihydrate USP, and 0.546 mg Glacial Acetic Acid USP; it is buffered with Sodium Hydroxide and/or Hydrochloric Acid with pH adjusted to 5.0 (4.5-5.5). The solution is sterile and non-pyrogenic. The package insert should be consulted for recommended dosage. The container must be checked for leaks before use; if leaks are found, the solution should be discarded. It should only be used if the solution is clear and colorless to light yellow; unused portions should be discarded. No additive should be introduced, and it should not be used in series connections. It is recommended to store it at controlled room temperature and avoid excessive heat. Baxter Healthcare Corporation produces it in the USA. If any confusion or wrong information found in the text, the description may not be accurate.*

This is a description of a pharmaceutical product called Esmnle Hydrochlu® 'de in Sodium Chlu:ite. The product is for single intravenous use only and must not be used if the overwrap is removed or damaged. The overwrap is necessary to maintain the sterility of the product. The solution is iso-osmotic and pH adjusted using sodium hydroxide and hydrochloric acid. The product should not be connected in series and should be stored at controlled room temperature. In case of leakage, the solution should be discarded as sterility may be compromised. The product should not be used with additives.*